U.S. Fertility Market to Gain Nearly $1B Over Next 5 Years

January 11, 2018

WELLESLEY, Mass., Jan 11, 2018 – The rising average age of new mothers and the growing number of single mothers are two key factors driving the demand for fertility clinics. In a new report, US Fertility Clinics Market, BCC Research estimates the market for fertility clinics in the United States should reach $3.6 billion and $4.5 billion in 2017 and 2022, respectively, indicating a compound annual growth rate (CAGR) of 4.6%.

This comprehensive report examines the critical market characteristics of the fertility market, including technological developments, the value chain, market dynamics and key market trends. Analyses include market breakdowns by diagnostics services and assisted reproductive technology. Government regulations, recent industry developments and the competitive landscape also are examined.

The increasing rates of obesity causing hormonal imbalances and problems with ovulation in women and low sperm quality in men, along with the decreasing fertility of women and the rising number of marriages in the LGBT community, are also driving market growth. The U.S. market for fertility clinics is fragmented with a few large players owning a small share of the market. Major market players mentioned in this report include IntegraMed, New Hope Fertility Clinic and Reproductive Medicine Associates of New Jersey, among many others.

Research Highlights

Assisted reproductive technology (ART) accounted for the largest share of the market in 2016 (70%).
Lack of insurance coverage for infertility treatments, risks of Assisted Reproductive Technology (ART), and cost and failure of vitro fertilization (IVF) represent market obstacles.
Vitro Maturation is an ART in which eggs are collected from a woman before they mature, which results in less drugs usage than previous approaches.

“New techniques for fertility treatment are helping drive this market,” said Robert G. Hunter, senior editor, healthcare. “For example, there are advancements in pre-genetic screening, which helps to lower the risks of transmitting genetic defects to offspring and miscarriage during IVF cycles. Furthermore, some clinics are also researching blastocyst transfer, which involves extending the culture period of IVF embryos for five to six days in the laboratory before transferring back to the woman’s uterus. Such advancements could significantly improve the efficacy of fertility treatments in the U.S.”

Editors/reporters requesting analyst interviews should contact steven.cumming@bccresearch.com.

Qualified members of the press can also request permission to access the BCC Research library.

US Fertility Clinics Market( HLC209A )
Publish Date: Dec 2017

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.